Search for "depression" in Full Text gives 34 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2014, 10, 1848–1877, doi:10.3762/bjoc.10.195
Graphical Abstract
Figure 1: Examples of phosphonamide reagents used in stereoselective synthesis.
Figure 2: Natural products and bioactive molecules synthesized using phosphonamide-based chemistry (atoms, bo...
Scheme 1: Olefination with cyclic phosphonamide anions, mechanistic rationale, and selected examples 27a–d [18].
Scheme 2: Asymmetric olefination with chiral phosphonamide anions and selected examples 31a–d [1,22].
Scheme 3: Synthesis of α-substituted phosphonic acids 33a–e by asymmetric alkylation of chiral phosphonamide ...
Scheme 4: Asymmetric conjugate additions of C2-symmetric chiral phosphonamide anions to cyclic enones, lacton...
Scheme 5: Asymmetric conjugate additions of P-chiral phosphonamide anions generated from 40a and 44a to cycli...
Scheme 6: Asymmetric cyclopropanation with chiral chloroallyl phosphonamide 47, mechanistic rationale, and se...
Scheme 7: Asymmetric cyclopropanation with chiral chloromethyl phosphonamide 28d [59].
Scheme 8: Stereoselective synthesis of cis-aziridines 57 from chiral chloroallyl phosphonamide 47a [62].
Scheme 9: Synthesis of phosphonamides by (A) Arbuzov reaction, (B) condensation of diamines with phosphonic a...
Figure 3: Original and revised structure of polyoxin A (69) [24-26].
Scheme 10: Synthesis of (E)-polyoximic acid (9) [24-26].
Figure 4: Key assembly strategy of acetoxycrenulide (10) [41,42].
Scheme 11: Total synthesis of (+)-acetoxycrenulide (10) [41,42].
Scheme 12: Synthesis squalene synthase inhibitor 19 by asymmetric sulfuration (A) and asymmetric alkylation (B...
Figure 5: Key assembly strategy of fumonisin B2 (20) and its tricarballylic acid fragment 105 [45,46].
Scheme 13: Final steps of the total synthesis of fumonisin B2 (20) [45,46].
Figure 6: Selected examples of two subclasses of β-lactam antibiotics – carbapenems (111 and 112) and trinems...
Scheme 14: Synthesis of tricyclic β-lactam antibiotic 123 [97].
Scheme 15: Total synthesis of (−)-anthoplalone (8) [56].
Figure 7: Protein tyrosine phosphatase (PTP) inhibitors 130, 131 and model compounds 16, 132 and 133 [68].
Scheme 16: Synthesis of model PTP inhibitors 16a,b [68].
Scheme 17: Synthesis of aziridine hydroxamic acid 17 as MMP inhibitor [63].
Scheme 18: Synthesis of methyl jasmonate (11) [48].
Figure 8: Structures of nudiflosides A (137) and D (13) [49].
Scheme 19: Total synthesis of the pentasubstituted cyclopentane core 159 of nudiflosides A (151) and D (13) an...
Figure 9: L-glutamic acid (161) and constrained analogues [57,124].
Scheme 20: Stereoselective synthesis of DCG-IV (162) [57].
Scheme 21: Stereoselective synthesis of mGluR agonist 21 [124].
Figure 10: Key assembly strategy of berkelic acid (15) [43].
Scheme 22: Total synthesis of berkelic acid (15) [43].
Figure 11: Key assembly strategy of jerangolid A (22) and ambruticin S (14) [27,28].
Scheme 23: Final assembly steps in the total synthesis of jerangolid A [27].
Scheme 24: Key assembly steps in the total synthesis of ambruticin S (14) [28].
Figure 12: General steroid construction strategy based on conjugate addition of 212 to cyclopentenone 48, exem...
Scheme 25: Total synthesis of estrone (12) [44].
Beilstein J. Org. Chem. 2014, 10, 1840–1847, doi:10.3762/bjoc.10.194
Graphical Abstract
Figure 1: Chemical structures and carbon numbering scheme of tricyclo(tc)-DNA (top, left), bicyclo(bc)-DNA (t...
Scheme 1: Conditions: (a) NaBH4, CeCl3·7H2O, MeOH, −78 °C → rt, 1.5 h, 73% (+9% of C6-epimer); (b) TBS-Cl, im...
Scheme 2: Conditions: (a) thymine, BSA, TMSOTf, TMSCl, CH3CN, rt, 2.5 h; (b) DMTrCl, pyridine, rt, 16 h, 29% ...
Figure 2: X-ray structure of top row: nucleosides 8β (left), 11β (center) and overlay of both structures (rig...
Scheme 3: Pathways for elimination of the modified nucleotides during the oxidation step in oligonucleotide a...
Beilstein J. Org. Chem. 2014, 10, 1114–1120, doi:10.3762/bjoc.10.110
Graphical Abstract
Figure 1: Glutamate receptor ligands.
Scheme 1: Proposed synthetic plan for the preparation of compound of type Ib.
Scheme 2: Synthesis of 3-azetidinone derivative 16.
Scheme 3: Synthetic routes to prepare target cyclopropyl derivatives 20. Reagents and conditions: a) (EtO)2PO...
Figure 2: Mechanism for the attack of the carbene intermediate to the olefin moiety 18.
Figure 3: Representation of the lowest energy conformation of each diastereoisomers.
Scheme 4: Synthesis of glutamate “frozen” analogues 4-carboxy-1-(ethoxycarbonyl)-5-azaspiro[2.3]hexane.
Beilstein J. Org. Chem. 2014, 10, 680–691, doi:10.3762/bjoc.10.61
Graphical Abstract
Scheme 1: Synthetic route for the synthesis of thiol functionalized 4-alkylphenols.
Scheme 2: Synthetic route for the chain transfer polymerization of N,N-diethylacrylamide (7) with CTA 6a and ...
Figure 1: Section of the MALDI –TOF spectrum of polymer 8b, indicating the high degree of end-group functiona...
Figure 2: 1H NMR spectrum of polymer 9b in CDCl3 (300 MHz, rt).
Figure 3: Top left: Section of the FTIR-spectrum of polymer 8b (black line) in comparison to 8bOx (red line);...
Figure 4: Dependency of the cloud point values on the degree of polymerization (calculated by end-group analy...
Figure 5: Shifts of the cloud points after the oxidation of the polymers (8a–d, 9a–d) to its corresponding su...
Figure 6: Turbidimetry measurements of polymer 8b (straight black line – heating curve; dotted black line – c...
Figure 7: 2D NMR NOESY spectrum of polymer 8b with two equivalents RAMEB-CD in D2O (600 MHz, rt).
Figure 8: Left: Schematic illustration of the micellar-like structures and reversibility by addition of RAMEB...
Figure 9: Schematic illustration of the micellar-like structures, its deformation upon addition of one equiva...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2012, 8, 1804–1813, doi:10.3762/bjoc.8.206
Graphical Abstract
Scheme 1: Three-step sequence for the preparation of γ-lactams from maleimides, aldehydes and amines. Potenti...
Scheme 2: The transfer of the diastereoselective ratio of 3 to the enantioselectivity of the overall process ...
Scheme 3: Combination of the Michael addition step with the reductive amination/lactamization step and of the...
Scheme 4: Combination of the Michael addition, the reductive amination/lactamization, and the epimerization s...
Scheme 5: Chemspeed 4 × 8 × 8 library of γ-lactams 6.
Beilstein J. Org. Chem. 2012, 8, 1657–1667, doi:10.3762/bjoc.8.190
Graphical Abstract
Scheme 1: Synthesis of the monosaccharide-substituted threonine building block (A = allo-L-threonine; B = D-t...
Scheme 2: Structures of monosaccharide-substituted AFGP analogues containing allo-L-threonine and L-alanine 5...
Figure 1: CD spectra of the monosaccharide-substituted AFGP analogues (5 and 7) and their corresponding aglyc...
Figure 2: (a) Temperature dependent CD spectra of the glycosylated allo-L-Thr containing peptide 5 from −10 t...
Figure 3: (a) Temperature-dependent CD spectra of the aglycon comprising allo-L-Thr 6 from −10 to 80 °C in wa...
Figure 4: (a) Temperature-dependent CD spectra of the glycosylated D-Thr and D-Ala containing peptide 7 from ...
Figure 5: Optical microphotographs taken after 0 and 120 min during the recrystallization process of polycrys...
Beilstein J. Org. Chem. 2011, 7, 59–74, doi:10.3762/bjoc.7.10
Graphical Abstract
Scheme 1: Synthesis of selective D3 receptor ligands.
Scheme 2: Synthesis of a novel 5-HT1B receptor antagonist.
Scheme 3: Synthesis of A-366833, a selective α4β2 neural nicotinic receptor agonist.
Scheme 4: A new route to oxcarbazepine.
Scheme 5: Synthesis of key intermediates for norepinephrine transporter (NET) inhibitors.
Scheme 6: N-Annulation yielding substituted indole for the synthesis of demethylasterriquinone A1.
Scheme 7: Palladium-catalysed double N-arylation contributing to the synthesis of murrazoline.
Scheme 8: Synthesis of vitamin E amines.
Scheme 9: Improved synthesis of martinellic acid.
Scheme 10: New tariquidar-derived ABCB1 inhibitors.
Scheme 11: β-Carbolin-1-ones as inhibitors of tumour cell proliferation.
Scheme 12: Copper-catalysed synthesis of promazine drugs.
Scheme 13: Palladium-catalysed multicomponent reaction for the synthesis of promazine drugs.
Scheme 14: Key intermediate for imatinib.
Scheme 15: Synthesis of an effective Chek1/KDR kinase inhibitor.
Scheme 16: Macrocyclization as final step of the synthesis of heat shock protein inhibitor.
Scheme 17: Synthesis of N-arylimidazoles.
Scheme 18: Synthesis of benzolactam V8.
Scheme 19: Synthesis of an intermediate for lotrafiban (SB-214857).
Scheme 20: Intermolecular effort towards lotrafiban.
Scheme 21: Synthesis of matrix metalloproteases (MMPs) inhibitor.
Scheme 22: Regioselective 9-N-arylation of purines.
Scheme 23: N-Arylation of adenine and cytosine.
Scheme 24: 9-N-Arylpurines as enterovirus inhibitors.
Scheme 25: Xanthine analogues as kinase inhibitors.
Scheme 26: Synthesis of dual PPARα/γ agonists.
Scheme 27: N-Aryltriazole ribonucleosides with anti-proliferative activity.
Beilstein J. Org. Chem. 2007, 3, No. 1, doi:10.1186/1860-5397-3-1
Graphical Abstract
Figure 1: Stereoview of the molecular structure of 2b, showing 50% probability displacement ellipsoids and th...
Figure 2: Stereoview of the packing of 2b. H atoms are not shown.
Scheme 1: Koreeda et al's proposed mechanism for the epimerization.